BLOG

In a recent episode of the Healthful Woman podcast, “Induction of labor and the ARRIVE trial,” podcast host Dr. Nathan Fox discusses induction of labor with Dr. Anum Naseem, an obstetrician/gynecologist at MFM Associates. They talk about the induction of labor and the ARRIVE trial, a study done to determine if induction increases the risk of C-section.

Why the ARRIVE Trial Was Conducted

Before the ARRIVE trial, most clinicians believed that inducing labor increased the chance of needing a C-section. As Dr. Fox explained, “When I was training, it was essentially like the word of God, that if you induce someone’s labor, you’re going to increase the risk of a C-section.” Earlier studies had compared people already in spontaneous labor with patients being induced, but this comparison did not reflect the decision patients actually face. Dr. Naseem shared that the real question is different, “The decision point is you get to 39 weeks. Do you want to be induced or do you want to wait?” The ARRIVE trial was designed to answer that question.

About The ARRIVE Trial

The ARRIVE trial was a randomized controlled trial, which is considered the highest-quality research method. It was conducted at 41 academic and community hospitals across the United States. Around 6,000 low-risk, first-time pregnant patients were enrolled. Each participant was randomly assigned to one of two paths: elective induction between 39 weeks and 39 weeks 4 days, or expectant management, meaning they would wait for labor to begin naturally or for a medical reason for induction to develop later.

Randomization was an essential component of the study because patients who prefer induction or clinicians who are more comfortable with one option could bias the results. Randomization ensured that the two groups were similar, allowing equal comparisons.

What the ARRIVE Trial Found

The study focused on the safety of induction for babies. Researchers examined a combination of newborn results, including NICU admission and the need for respiratory support. The results showed no difference between the induction group and the group that waited. About 4% of babies in the induction group and 5% in the expectant-management group experienced complications included in the composite measure. This finding showed that elective induction at 39 weeks is a safe option for babies.

The study also evaluated maternal health. The rate of C-section was lower among patients who underwent elective induction. Although this was a secondary finding and not the main objective of the study, it contradicted long-standing assumptions. The risk of developing pregnancy-related hypertension was also lower in the induction group, because continuing a pregnancy longer allows more time for high blood pressure to develop.

The ARRIVE Trial’s Limitations

Although the trial showed that induction at 39 weeks is safe, the podcast also addressed practical limitations. Induction for a first-time parent often requires 12 to 24 hours in the hospital. Hospitals with large labor units, such as Northwestern, can handle this volume. In smaller hospitals, however, widespread elective induction may not be possible because it can fill labor rooms for long periods and limit space for patients who need care.

The doctors also noted a difference between research settings and everyday labor floors. In the study, clinicians followed strict timelines, waited the full length of an induction, and avoided performing C-sections early. Outside of a study, some patients or clinicians may not want to wait through a long induction, which can affect results.

What This Means for Patients

The ARRIVE trial shows that elective induction at 39 weeks is a safe and reasonable option for low-risk, first-time pregnancies. It does not increase C-section rates or worsen outcomes for babies. Patients who prefer more control over timing, who feel ready for delivery, or who want to avoid the risk of developing hypertension may consider induction. Patients who prefer to wait for spontaneous labor can also do so safely.

Learn More

To hear the full discussion about induction and the ARRIVE trial, listen to the complete episode of the Healthful Woman podcast. For additional information or pregnancy care, contact Maternal Fetal Medicine Associates in New York City by completing the online contact form.

Maternal Fetal Medicine blogs are intended for educational purposes only and do not replace certified professional care. Medical conditions vary and change frequently. Please ask your doctor any questions you may have regarding your condition to receive a proper diagnosis or risk analysis. Thank you!